Abstract: An amorphous solid dispersion includes a linear poly(acrylic acid) and an active pharmaceutical ingredient. The linear poly(acrylic acid) used to form the amorphous solid dispersion has a Brookfield viscosity of at least 100 cP at 25° C. A method of forming such an amorphous solid dispersion of an active pharmaceutical ingredient includes forming a liquid dispersion of a linear poly(acrylic acid), an active pharmaceutical ingredient, and a solvent system, the linear poly(acrylic acid) having a Brookfield viscosity at 25° C. of at least 100 cP and evaporating the solvent system from the liquid dispersion to form an amorphous solid dispersion.

Abstract: The disclosed technology provides improved drug compositions that provide increased stability, higher drug loading potential, and suitable drug dissolution properties, and methods of making the same. The composition include: (a) a drug component comprising a therapeutically effective amount of a drug; (b) an extended release component comprising a cross-linked polyacrylic acid polymer that is a carbomer homopolymer, carbomer copolymer, carbomer interpolymer, polycarbophil or a mixture thereof; and (c) a buffering component comprising a magnesium containing buffering agent; wherein the drug component makes up at least 50% by weight of the composition.

Abstract: The disclosed technology provides improved drug compositions that provide increased stability, higher drug loading potential, and suitable drug dissolution properties, and methods of making the same. The composition include: (a) a drug component comprising a therapeutically effective amount of a drug; (b) an extended release component comprising a cross-linked polyacrylic acid polymer that is a carbomer homopolymer, carbomer copolymer, carbomer interpolymer, polycarbophil or a mixture thereof; and (c) a buffering component comprising a magnesium containing buffering agent; wherein the drug component makes up at least 50% by weight of the composition.

Abstract: A homogenous film formed from a cross-linked poly(acrylic) acid and a thermoplastic polyurethane composition is disclosed. The film exhibits fluid absorption properties and good mechanical properties. The films provide useful materials for medical and pharmaceutical applications.

Abstract: An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose and a binder, and optionally a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility, and increased API loading and blendability as compared to the individual components, and as compared to conventional excipients formed from the same materials. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API.

Abstract: A homogenous film formed from a cross-linked poly(acrylic) acid and a thermoplastic polyurethane composition is disclosed. The film exhibits fluid absorption properties and good mechanical properties. The films provide useful materials for medical and pharmaceutical applications.

Abstract: A low dose API pharmaceutical tablet having excellent content uniformity is provided. The tablet is formed by spray coating a support excipient with the API. The resulting composition is suitable for direct compression tablet formulation without the need for an additional granulation step to uniformly coat the API onto the support excipient. The support excipient comprises microcrystalline cellulose, a binder and a disintegrant, and is formed by spraying a homogeneous slurry of the support excipient components.

Abstract: An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose and a binder, and optionally a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility, and increased API loading and blendability as compared to the individual components, and as compared to conventional excipients formed from the same materials. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API.

Abstract: An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular dibasic calcium phosphate based excipient is provided. The improved excipient comprises dibasic calcium phosphate, a binder and a disintegrant, and is formed by spraying a homogeneous slurry of the components. The improved excipient provides enhanced flowability/good flow properties, an increased API loading and blendability and higher compactibility as compared to the individual components, and as compared to excipients formed from the same materials by conventional methods. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API.

Abstract: A sustained release composition comprising spray dried particles of at least one polysaccharide gum and at least one polyhydric sugar alcohol, as well as methods of making the sustained released composition are provided. A sustained release pharmaceutical solid dosage form, and a method of making the solid dosage form by compression are also provided.

Abstract: An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose, a binder and a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility, and increased API loading and blendability as compared to the individual components, and as compared to conventional excipients formed from the same materials. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API.

Abstract: An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose and a binder, and optionally a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility, and increased API loading and blendability as compared to the individual components, and as compared to conventional excipients formed from the same materials. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API.